Casdin Capital

The at-home diagnostics provider closed its high-flying series D with support from a handful of longtime backers that included Illumina Ventures, UnitedHealth's Optum Ventures and golfer Rory McIlroy, through his own Symphony Ventures.

C2i Genomics, which is developing a blood test to detect residual cancer cells after tumor removal, just closed $100 million in new funding, nearly 10 times the size of the series A it racked up less than a year ago.

C2i Genomics, a cancer intelligence company, today announced $100 million in financing led by Casdin Capital with participation from NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others. The funding will accelerate clinical development and commercialization of the company's C2-Intelligence Platform, a cancer diagnostics service that uses AI pattern recognition and whole-genome analysis to provide rapid and accurate detection of residual disease that is up...

CM Life Sciences III Inc. (the " Company ") announced today that it closed its initial public offering of 55,200,000 units at $10.00 per unit, including 7,200,000 units issued pursuant to the exercise in full by the underwriters of its over-allotment option.

Cleo Health hauled in $40 million to scale up its family benefits platform for working parents and families, BrightInsight banked $101 million to grow its digital health platform for biopharma and medtech companies and more funding news in March.

Healthcare "map maker" Komodo Health netted $220 million in new funding to build out its data analytics platform for life sciences research. The startup has created a massive "healthcare map," an artificial intelligence platform that compiles de-identified healthcare data from hundreds of sources and more than 325 million individual patients.

After scoring two European approvals last month for its artificial-intelligence-powered cancer pathology platforms, Paige has secured $100 million in new funding to boost its development of biomarkers as clinical applications.

BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced two new co-investments with innovation accelerator partner Casdin Capital.